Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Am J Gastroenterol. 2021 Jul 1;116(7):1406-1413. doi: 10.14309/ajg.0000000000001228.
Although opioid use disorder (OUD) is common in patients with cirrhosis, it is unclear how medication treatment for OUD (MOUD) is used in this population. We aimed to assess the factors associated with MOUD and mortality in a cohort of Veterans with cirrhosis and OUD.
Within the Veterans Health Administration Corporate Data Warehouse, we developed a cohort of Veterans with cirrhosis and active OUD, using 2 outpatient or 1 inpatient International Classification of Diseases, ninth revision codes from 2011 to 2015 to define each condition. We assessed MOUD initiation with methadone or buprenorphine over the 180 days following the first OUD International Classification of Diseases, ninth revision code in the study period. We fit multivariable regression models to assess the association of sociodemographic and clinical factors with receiving MOUD and the associations between MOUD and subsequent clinical outcomes, including new hepatic decompensation and mortality.
Among 5,600 Veterans meeting criteria for active OUD and cirrhosis, 722 (13%) were prescribed MOUD over 180 days of follow-up. In multivariable modeling, MOUD was significantly, positively associated with age (adjusted odds ratio [AOR] per year: 1.04, 95% confidence interval (CI): 1.01-1.07), hepatitis C virus (AOR = 2.15, 95% CI = 1.37-3.35), and other substance use disorders (AOR = 1.47, 95% CI = 1.05-2.04) negatively associated with alcohol use disorder (AOR = 0.70, 95% CI = 0.52-0.95), opioid prescription (AOR = 0.51, 95% CI = 0.38-0.70), and schizophrenia (AOR = 0.59, 95% CI = 0.37-0.95). MOUD was not significantly associated with mortality (adjusted hazards ratio = 1.20, 95% CI = 0.95-1.52) or new hepatic decompensation (OR = 0.57, CI = 0.30-1.09).
Few Veterans with active OUD and cirrhosis received MOUD, and those with alcohol use disorder, schizophrenia, and previous prescriptions for opioids were least likely to receive these effective therapies.
尽管阿片类药物使用障碍(OUD)在肝硬化患者中很常见,但尚不清楚在该人群中如何使用 OUD 的药物治疗(MOUD)。我们旨在评估退伍军人肝硬化和 OUD 队列中 MOUD 和死亡率相关的因素。
在退伍军人健康管理局公司数据仓库中,我们通过 2011 年至 2015 年的 2 个门诊或 1 个住院国际疾病分类第 9 版代码,为患有肝硬化和活跃 OUD 的退伍军人建立了队列,以定义每种疾病。我们在研究期间,评估了在 180 天内,使用美沙酮或丁丙诺啡开始 MOUD 的情况。我们通过多变量回归模型评估了社会人口统计学和临床因素与接受 MOUD 之间的关联,以及 MOUD 与随后的临床结果(包括新的肝失代偿和死亡率)之间的关联。
在符合活跃 OUD 和肝硬化标准的 5600 名退伍军人中,有 722 名(13%)在 180 天的随访中接受了 MOUD。在多变量建模中,MOUD 与年龄呈显著正相关(每年调整后的优势比 [AOR]:1.04,95%置信区间 [CI]:1.01-1.07)、丙型肝炎病毒(AOR = 2.15,95%CI = 1.37-3.35)和其他物质使用障碍(AOR = 1.47,95%CI = 1.05-2.04)呈负相关,而与酒精使用障碍(AOR = 0.70,95%CI = 0.52-0.95)、阿片类药物处方(AOR = 0.51,95%CI = 0.38-0.70)和精神分裂症(AOR = 0.59,95%CI = 0.37-0.95)呈负相关。MOUD 与死亡率(调整后的危险比= 1.20,95%CI = 0.95-1.52)或新的肝失代偿(OR = 0.57,CI = 0.30-1.09)无显著相关性。
很少有活跃的 OUD 和肝硬化退伍军人接受 MOUD,而有酒精使用障碍、精神分裂症和以前阿片类药物处方的退伍军人最不可能接受这些有效的治疗方法。